Sysmex Corporation ADR (OTCMKTS:SSMXY) Short Interest Down 42.7% in February

Sysmex Corporation ADR (OTCMKTS:SSMXY) was the recipient of a significant decrease in short interest in February. As of February 13th, there was short interest totaling 65,013 shares, a decrease of 42.7% from the January 29th total of 113,501 shares. Currently, 0.0% of the shares of the company are short sold. Based on an average daily volume of 442,397 shares, the days-to-cover ratio is currently 0.1 days. Based on an average daily volume of 442,397 shares, the days-to-cover ratio is currently 0.1 days. Currently, 0.0% of the shares of the company are short sold.

Sysmex Price Performance

OTCMKTS SSMXY opened at $9.38 on Friday. Sysmex has a one year low of $8.15 and a one year high of $19.85. The stock has a 50-day moving average of $9.54 and a 200 day moving average of $10.84. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.49 and a current ratio of 3.34. The company has a market capitalization of $5.90 billion, a price-to-earnings ratio of 19.54 and a beta of 1.14.

Sysmex (OTCMKTS:SSMXY) last announced its quarterly earnings results on Thursday, February 12th. The company reported $0.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.01. Sysmex had a net margin of 8.86% and a return on equity of 9.32%. The firm had revenue of $837.32 million for the quarter, compared to the consensus estimate of $819.99 million. On average, sell-side analysts forecast that Sysmex will post 0.57 EPS for the current year.

Sysmex Company Profile

Sysmex Corporation (OTCMKTS: SSMXY) is a Japan‐based provider of in vitro diagnostic solutions, specializing in haematology, coagulation, urinalysis and immunochemistry systems. Headquartered in Kobe, the company designs and manufactures a comprehensive portfolio of automated analyzers, reagents and software to support clinical laboratories, hospitals and research institutions. Sysmex’s product lineup also includes digital pathology platforms and data management tools that integrate workflow automation and advanced analytics.

The company’s core offerings center on haematology analyzers such as the XN-Series, which deliver high‐speed, high‐volume testing for blood cell counts and differential analysis.